Table of Contents
- A clear guide to GLP-1 medications
- What GLP-1 medications actually do
- Currently available FDA-approved options
- Injectable vs. oral: what to know
- Side effects: what is common, what to watch for
- When GLP-1 medications may not be appropriate
- Medication questions we hear often
- Want the complete picture?
- Questions about which medication fits your situation?
A clear guide to GLP-1 medications
Written by a physician, not a marketing team. The goal here is to give you enough real information to have a meaningful conversation about what may be right for your situation.
What GLP-1 medications actually do
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after eating. It helps regulate blood sugar, slows gastric emptying, and signals to the brain that you have eaten enough.
GLP-1 receptor agonist medications mimic this hormone’s action at a sustained level, which can significantly reduce appetite, improve blood sugar control, and in many patients, support meaningful and sustained weight loss.
These medications work at the level of biology, not willpower. For the right patient, that distinction matters enormously.
FDA-approved uses include:
- Type 2 diabetes management
- Chronic weight management in adults with obesity
- Chronic weight management in overweight adults with a weight-related condition
- Cardiovascular risk reduction in certain high-risk patients
Note: FDA approval status varies by specific medication and indication. What is appropriate for you depends on your medical history and goals.
Currently available FDA-approved options
An educational overview, not a prescribing recommendation. Indications and availability evolve; consult a physician for guidance on your situation.
This overview reflects FDA approvals and general clinical positioning as of early 2026. Indications, availability, and approved uses evolve. Consult a physician for current guidance on what is appropriate for your situation.
Injectable vs. oral: what to know
Form factor matters to patients. Here is an honest comparison.
Semaglutide and tirzepatide injectables
One injection per week using a pen-style auto-injector. Most patients who were initially reluctant find the process straightforward after the first dose. More consistent drug levels in the body compared to oral forms. Strongest clinical trial data for weight loss outcomes. Widest availability including brand-name and, in some cases, insurance-covered forms.
Oral semaglutide (Rybelsus / oral Wegovy)
A daily tablet with no injection required. Must be taken fasting, 30 minutes before anything else in the morning. Absorption is more variable than injectable forms. Clinical weight loss data is developing, especially for the oral Wegovy formulation. Likely to become a popular choice as access and approvals continue to expand. Worth discussing specifically if injections are a barrier for you.
Side effects: what is common, what to watch for
Honesty about side effects is part of a real medical evaluation. Here is what the evidence shows.
What most patients experience at some point
Nausea is the most common side effect and usually improves with dose titration. Vomiting is less frequent and often dose-related. Diarrhea or constipation, decreased appetite, and fatigue during early ramp-up are all well-documented and often manageable with the right support.
What to be aware of over time
Heartburn or acid reflux, slowed gastric emptying, hair thinning, and loss of lean mass can occur in some patients. These are part of why protein intake, strength-focused movement, hydration, and medication review matter in a thoughtful long-term plan.
Discuss specifically with your physician
Pancreatitis, gallbladder disease, thyroid C-cell tumor warning considerations, worsening retinopathy in some patients with diabetes, and kidney injury in the setting of severe dehydration deserve specific review before and during treatment.
FDA boxed warning: GLP-1 medications carry a warning regarding thyroid C-cell tumors based on animal studies. This is a contraindication for patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. A proper medical evaluation should review this specifically.
When GLP-1 medications may not be appropriate
A good physician tells you both when something is likely to help and when it may not be the right fit.
Situations where these medications are not appropriate
Personal or family history of medullary thyroid carcinoma. Multiple Endocrine Neoplasia type 2 (MEN2). Prior serious hypersensitivity reaction to a GLP-1 medication. History of pancreatitis in certain clinical contexts. Pregnancy or active plans for near-term pregnancy.
Situations requiring individualized evaluation
Multiple concurrent medications with significant GI or absorption effects. Active or recent eating disorder history. Significant history of gastroparesis. Severe renal or hepatic impairment. History of serious cardiovascular events (some medications in this class may actually be beneficial; evaluation is required to sort that out).
Medication questions we hear often
How long do I need to take these medications?
This varies by patient and goal. For weight management, most clinical evidence suggests that weight tends to return when the medication is stopped, which means long-term treatment is often part of the plan for patients whose primary goal is sustained weight loss. Some patients eventually taper successfully. Others choose to continue indefinitely at a maintenance dose. This is something to plan and revisit over time, not decide in advance.
What is the difference between Wegovy and Ozempic?
Both contain semaglutide. The difference is in the FDA-approved indication, dosing range, and how they are labeled and prescribed. Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy is approved for chronic weight management in adults with obesity or overweight with a related condition. Wegovy’s approved maximum dose is higher than Ozempic’s.
Is tirzepatide more effective than semaglutide?
Head-to-head clinical trials suggest tirzepatide produces greater average weight loss than semaglutide in the populations studied. Individual results vary considerably. Some patients respond better to one than the other. Cost, access, insurance coverage, and prior experience are all factors in the decision, not just the headline trial numbers.
What about compounded semaglutide?
Compounded semaglutide was widely available during the period when brand-name semaglutide was on the FDA shortage list. As of early 2026, the FDA has ended the shortage designation, which significantly changes the legal and regulatory landscape for compounded versions. We do not currently prescribe compounded GLP-1 medications. We prescribe FDA-approved brand-name options.
How much does medication cost?
Medication costs depend heavily on your insurance coverage, any manufacturer savings programs you qualify for, and the pharmacy you use. Without coverage, brand-name injectables can be expensive, though manufacturer programs have reduced costs significantly for commercially insured patients. This is worth discussing during the consultation. We will help you think through realistic access options for your situation.
Want the complete picture?
The full GLP-1 Medication Guide goes deeper: every FDA-approved brand compared side by side, complete dose ladders from introductory to maintenance, oral versus injectable tradeoffs clearly explained, and a breakdown of access models and monitoring approaches. If you are doing thorough research before deciding, this is where to go.
Questions about which medication fits your situation?
This is exactly what a thorough consultation is for. Bring your questions. There are no wrong ones.